NAICS 325412 Quarterly Industry Report
Pharmaceutical Preparation Manufacturing
Comprehensive industry research for valuation professionals, business owners, buyers, and lenders
NAICS Code: 325412Sector: 32Updated: Q1 2026
About This Report
This Fair Market Value industry report for NAICS 325412 provides business owners, acquirers, and financial advisors with data-driven valuation insights for the pharmaceutical preparation manufacturing sector, drawing on data from the U.S. Census Bureau[5] and FDA[9] drug product manufacturing statistics. Additional data is drawn from Bureau of Labor Statistics[10].. The report aggregates transaction multiples, financial benchmarks, and market trends specific to NAICS 325412 establishments, supporting buy-sell agreements, succession planning, SBA-financed acquisitions, and litigation support engagements.
Industry Snapshot
Key metrics for the pharmaceutical preparation manufacturing industry.
Industry Definition & Overview
Pharmaceutical Preparation Manufacturing (NAICS 325412) encompasses establishments primarily engaged in manufacturing pharmaceutical preparations intended for internal and external consumption in finished dosage forms, including tablets, capsules, ampoules, vials, ointments, powders, solutions, and suspensions, as well as in-vivo diagnostic substances. According to the U.S. Census Bureau[5], approximately 1,726 companies operate within this classification, employing over 167,000 workers in manufacturing facilities that produced over $177 billion in annual revenue, making it one of the largest manufacturing industries in the United States by output value.
Product categories span branded prescription pharmaceuticals, generic drug products, over-the-counter medications, and specialty pharmaceutical preparations including sterile injectables, transdermal drug delivery systems, and controlled-release formulations. The International Trade Administration[6] reports U.S. pharmaceutical preparation imports exceeding $82 billion and exports of $26 billion, reflecting the global nature of pharmaceutical supply chains and the domestic market's position as the world's largest pharmaceutical consumer. The Bureau of Labor Statistics[7] identifies production roles including tablet press operators, sterile filling technicians, pharmaceutical scientists developing formulation and process parameters, quality control analysts performing dissolution and stability testing, and validation engineers qualifying manufacturing equipment and processes under cGMP requirements.
Per the SBA Office of Advocacy[8], the industry spans large multinational pharmaceutical corporations with global manufacturing networks to smaller contract manufacturers, generic drug producers, and specialty pharmaceutical companies focused on niche therapeutic areas or dosage form technologies. The generic pharmaceutical segment has expanded as major branded drugs lose patent protection, creating growth opportunities for companies specializing in abbreviated new drug application development and commercial-scale generic drug manufacturing.
What's Included in This Industry
- Valuation multiples benchmarked to pharmaceutical preparation manufacturing operations
- Revenue and EBITDA trends for domestic pharmaceutical dosage form production
- SBA lending data and financing terms for NAICS 325412 businesses
- Comparable transaction data from recent pharmaceutical manufacturer acquisitions
- Industry risk factors including FDA compliance, patent cliffs, and pricing pressure
- Workforce composition and labor cost benchmarks for cGMP manufacturing operations
- Regional market analysis covering pharmaceutical production clusters
- Capital expenditure benchmarks for tablet press, sterile fill, and packaging equipment
- Growth projections tied to generic drug development and specialty pharmaceutical demand
- Owner compensation and discretionary earnings benchmarks
NAICS Classification Hierarchy
| Level | Description | Code |
|---|---|---|
| Subsector | Chemical Manufacturing | 325 |
| Industry Group | Pharmaceutical and Medicine Manufacturing | 3254 |
| NAICS Industry | Pharmaceutical and Medicine Manufacturing | 32541 |
| National Industry | Pharmaceutical Preparation Manufacturing | 325412 |
Related NAICS Codes
| Code | Description | Relationship |
|---|---|---|
| 325411 | Medicinal and Botanical Manufacturing | Medicinal and botanical manufacturers producing active pharmaceutical ingredients and botanical extracts consumed as primary inputs in pharmaceutical dosage form production |
| 325414 | Biological Product (except Diagnostic) Manufacturing | Biological product manufacturers producing vaccines, blood fractions, and biologic therapies through parallel cGMP manufacturing processes within the pharmaceutical sector |
| 325413 | In-Vitro Diagnostic Substance Manufacturing | In-vitro diagnostic substance manufacturers sharing pharmaceutical-grade production infrastructure and FDA regulatory compliance requirements with drug product producers |
| 424210 | Drugs and Druggists' Sundries Merchant Wholesalers | Drug and druggist sundries merchant wholesalers distributing finished pharmaceutical preparations from manufacturers to retail pharmacies and hospital systems |
| 339115 | Ophthalmic Goods Manufacturing | Ophthalmic goods manufacturing establishments producing medicated eye care products that overlap with pharmaceutical preparation dosage form categories |
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | Biotechnology research and development laboratories generating new drug candidates that create manufacturing demand for pharmaceutical dosage form production capacity |
Geographic Concentration
Top states by share of national establishments.
| # | State | % Est. | Total Est. |
|---|---|---|---|
| 1 | California | 16.1% | 232 |
| 2 | New Jersey | 8.8% | 126 |
| 3 | Florida | 7.4% | 106 |
| 4 | New York | 6.3% | 90 |
| 5 | Texas | 5.2% | 74 |
| 6 | Massachusetts | 4.8% | 69 |
| 7 | Colorado | 3.6% | 52 |
| 8 | Pennsylvania | 3.3% | 47 |
| 9 | North Carolina | 3.1% | 44 |
| 10 | Utah | 3.1% | 44 |
% Of Establishments
0%
16%
Source: County Business Patterns, U.S. Census Bureau[3]
SBA Lending Summary
200
Total SBA Loans
$188.8M
Total Loan Volume
$944K
Average Loan Size
9 yrs
Average Loan Term
10.13%
Average Interest Rate
2,096
Jobs Supported
Source: SBA 7(a) Program Data, U.S. Small Business Administration — FY 2025[4]
Key Insight: Pharmaceutical manufacturers evaluating SBA financing must consider qualification under the SBA size standards[11] for NAICS 325412, which set the threshold at 1,250 employees for small business classification. The SBA 7(a) loan program[12] supports smaller generic manufacturers, contract packaging operations, and specialty pharmaceutical companies acquiring businesses or financing working capital, while the CDC/504 loan program[13] provides long-term fixed-rate financing for tablet presses, sterile filling lines, packaging equipment, and cGMP facility buildouts. Lenders evaluate FDA facility approval status, ANDA portfolio value, and customer contract stability when structuring pharmaceutical manufacturing loans.
Top SBA Lenders
| # | Lender | Loans | Volume | Avg Loan |
|---|---|---|---|---|
| 1 | Firstrust Savings Bank | 32 | $35.5M | $1.1M |
| 2 | Customers Bank | 16 | $28.2M | $1.8M |
| 3 | Newtek Bank, National Association | 32 | $23.2M | $725K |
| 4 | Celtic Bank Corporation | 8 | $23.1M | $2.9M |
| 5 | Live Oak Banking Company | 8 | $22.4M | $2.8M |
Frequently Asked Questions
Common questions about this industry.
What is the typical valuation multiple for a pharmaceutical manufacturer?
Pharmaceutical preparation manufacturers typically trade at 8x to 15x EBITDA, with branded drug companies commanding premium multiples and generic manufacturers at the lower end. Per U.S. Census Bureau[5] data, the industry's 1,726 firms vary enormously from large multinational corporations to smaller contract manufacturers valued on capacity and compliance status.
What SBA loan options are available for pharmaceutical manufacturing businesses?
The SBA[11] sets the small business threshold at 1,250 employees for NAICS 325412. SBA financing primarily serves smaller generic manufacturers, contract packagers, and specialty pharmaceutical companies, with 7(a) loans supporting acquisitions and 504 loans financing manufacturing equipment investments.
What FDA requirements affect pharmaceutical preparation manufacturers?
The FDA[9] requires pharmaceutical manufacturers to register establishments, obtain new drug or abbreviated new drug approvals for each product, comply with cGMP regulations, submit to periodic facility inspections, and maintain validated manufacturing processes, analytical methods, and quality systems.
How does generic competition affect pharmaceutical industry valuations?
Patent expirations on branded drugs create entry opportunities for generic manufacturers filing ANDAs with the FDA[9]. First-to-file generic applicants receive 180-day exclusivity periods that can generate substantial revenues, while subsequent generic entrants compete on price, driving margins down over time.
What are the growth drivers for pharmaceutical preparation manufacturing?
Aging population demographics, specialty drug development, biosimilar competition, and contract manufacturing outsourcing drive industry growth. Per the FDA[9], record numbers of generic drug approvals and new molecular entity approvals support manufacturing volume growth and capacity expansion investment.
How does drug pricing regulation affect manufacturers?
Federal and state drug pricing initiatives including Medicare Part D negotiation authority and state transparency requirements create pricing pressure on pharmaceutical manufacturers. Per the Centers for Medicare and Medicaid Services[14], pricing regulations primarily affect branded drug manufacturers while creating some margin compression for generic producers.
What workforce challenges do pharmaceutical manufacturers face?
The Bureau of Labor Statistics[7] reports strong demand for pharmaceutical scientists, cGMP manufacturing specialists, quality assurance professionals, and sterile processing technicians. Competition among pharmaceutical manufacturers for trained personnel is intense in established production clusters.
How does contract manufacturing affect the pharmaceutical industry?
Outsourcing of pharmaceutical manufacturing to contract development and manufacturing organizations has grown as branded and generic companies seek capital efficiency. Per the FDA[9], CDMOs must maintain the same cGMP compliance standards as brand-owner facilities, with FDA inspection history directly affecting contract manufacturer valuations.
Sources & References
Government datasets and editorial sources used in this report.
- [1]U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages bls.gov
- [2]U.S. Census Bureau, Economic Census census.gov
- [3]U.S. Census Bureau, County Business Patterns census.gov
- [4]U.S. Small Business Administration, SBA 7(a) Loan Program Data data.sba.gov
- [5]U.S. Census Bureau census.gov
- [6]International Trade Administration trade.gov
- [7]Bureau of Labor Statistics bls.gov
- [8]SBA Office of Advocacy advocacy.sba.gov
- [9]FDA fda.gov
- [10]Bureau of Labor Statistics bls.gov
- [11]SBA size standards sba.gov
- [12]SBA 7(a) loan program sba.gov
- [13]CDC/504 loan program sba.gov
- [14]Centers for Medicare and Medicaid Services cms.gov
Disclaimer
This publication has been prepared by Fair Market Value (“Fair Market Value”) for informational purposes only. It is provided on an “as-is” and “as available” basis. Fair Market Value makes no representations or warranties, express or implied, regarding the merchantability, fitness for a particular purpose, completeness, or accuracy of the data or information contained herein. This publication is not intended to be, and should not be construed as, professional financial, legal, tax, or investment advice. Users should consult with qualified professionals before making any financial or business decisions based on the information presented.
To the extent permitted by law, Fair Market Value disclaims all liability for loss or damage, direct and indirect, suffered or incurred by any person resulting from the use of, or reliance upon, the data in this publication.
Copyright © 2026 Fair Market Value. All rights reserved. All data, information, articles, graphs, and content contained in this publication are copyrighted works and Fair Market Value hereby reserves all rights. No part of this publication may be copied, reproduced, republished, uploaded to a third party, or distributed without the prior written permission of Fair Market Value.